CH638562A5 - Process for obtaining a cleavage product of rabies virus - Google Patents

Process for obtaining a cleavage product of rabies virus Download PDF

Info

Publication number: CH638562A5
Authority: CH; Switzerland
Prior art keywords: cleavage; fraction; rabies virus; virus; obtaining
Prior art date: 1976-02-12

Application number

CH170977A

Other languages

German (de)

English (en)

Inventor

Lothar Gerhard Prof Schneider

Bernhard Dr Dietzschold

James Hilton Dr Cox

Original Assignee

Behringwerke Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-02-12

Filing date

1977-02-11

Publication date

1983-09-30

1977-02-11 Application filed by Behringwerke Ag filed Critical Behringwerke Ag

1983-09-30 Publication of CH638562A5 publication Critical patent/CH638562A5/de

Links

238000003776 cleavage reaction Methods 0.000 title claims description 21
230000007017 scission Effects 0.000 title claims description 21
241000711798 Rabies lyssavirus Species 0.000 title claims description 14
238000000034 method Methods 0.000 title claims description 8
239000000047 product Substances 0.000 claims description 10
241000700605 Viruses Species 0.000 claims description 9
102000003886 Glycoproteins Human genes 0.000 claims description 8
108090000288 Glycoproteins Proteins 0.000 claims description 8
238000001155 isoelectric focusing Methods 0.000 claims description 6
238000000926 separation method Methods 0.000 claims description 5
239000002736 nonionic surfactant Substances 0.000 claims description 3
102000011931 Nucleoproteins Human genes 0.000 claims description 2
108010061100 Nucleoproteins Proteins 0.000 claims description 2
230000002163 immunogen Effects 0.000 claims 2
239000004094 surface-active agent Substances 0.000 claims 2
XSXWOBXNYNULJG-UHFFFAOYSA-N 2-(2,4,4-trimethylpentan-2-yl)phenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1O XSXWOBXNYNULJG-UHFFFAOYSA-N 0.000 claims 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
108010052285 Membrane Proteins Proteins 0.000 claims 1
239000007795 chemical reaction product Substances 0.000 claims 1
229920002113 octoxynol Polymers 0.000 claims 1
239000013504 Triton X-100 Substances 0.000 description 7
229920004890 Triton X-100 Polymers 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
238000004113 cell culture Methods 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000000725 suspension Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
239000003599 detergent Substances 0.000 description 1
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
150000004676 glycans Polymers 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

CH170977A 1976-02-12 1977-02-11 Process for obtaining a cleavage product of rabies virus CH638562A5 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2605469A DE2605469C3 (de)	1976-02-12	1976-02-12	Verfahren zur Gewinnung eines Spaltprodukts des Tollwut-Virus und dieses enthaltender Impfstoff

Publications (1)

Publication Number	Publication Date
CH638562A5 true CH638562A5 (en)	1983-09-30

Family

ID=5969649

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH170977A CH638562A5 (en)	1976-02-12	1977-02-11	Process for obtaining a cleavage product of rabies virus

Country Status (15)

Country	Link
JP (1)	JPS5299209A (fr)
AT (1)	AT350715B (fr)
BE (1)	BE851404A (fr)
CA (1)	CA1087982A (fr)
CH (1)	CH638562A5 (fr)
DE (1)	DE2605469C3 (fr)
DK (1)	DK145580C (fr)
FR (1)	FR2340955A1 (fr)
GB (1)	GB1567547A (fr)
IE (1)	IE44440B1 (fr)
IL (1)	IL51412A (fr)
IT (1)	IT1075115B (fr)
LU (1)	LU76737A1 (fr)
NL (1)	NL7701255A (fr)
OA (1)	OA05567A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0049296B1 (fr) *	1980-10-02	1985-03-27	Schering Corporation	Composition de vaccin antirabique injectable et procédé pour sa préparation
ES2991988T3 (es)	2017-10-30	2024-12-05	Takeda Pharmaceuticals Co	Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica

1976
- 1976-02-12 DE DE2605469A patent/DE2605469C3/de not_active Expired
1977
- 1977-02-03 FR FR7703023A patent/FR2340955A1/fr active Granted
- 1977-02-07 NL NL7701255A patent/NL7701255A/xx not_active Application Discontinuation
- 1977-02-10 IT IT20166/77A patent/IT1075115B/it active
- 1977-02-10 LU LU76737A patent/LU76737A1/xx unknown
- 1977-02-10 OA OA56069A patent/OA05567A/fr unknown
- 1977-02-10 GB GB5495/77A patent/GB1567547A/en not_active Expired
- 1977-02-10 IL IL51412A patent/IL51412A/xx unknown
- 1977-02-11 CH CH170977A patent/CH638562A5/de not_active IP Right Cessation
- 1977-02-11 IE IE293/77A patent/IE44440B1/en unknown
- 1977-02-11 CA CA271,602A patent/CA1087982A/fr not_active Expired
- 1977-02-11 DK DK59377A patent/DK145580C/da active
- 1977-02-11 AT AT92877A patent/AT350715B/de not_active IP Right Cessation
- 1977-02-12 JP JP1353277A patent/JPS5299209A/ja active Pending
- 1977-02-14 BE BE174916A patent/BE851404A/fr not_active IP Right Cessation

Also Published As

Publication number	Publication date
LU76737A1 (fr)	1977-08-19
CA1087982A (fr)	1980-10-21
IL51412A (en)	1980-05-30
DE2605469B2 (de)	1979-08-02
JPS5299209A (en)	1977-08-19
FR2340955A1 (fr)	1977-09-09
DK145580B (da)	1982-12-13
AT350715B (de)	1979-06-11
DK145580C (da)	1983-05-16
IE44440L (en)	1977-08-12
ATA92877A (de)	1978-11-15
DE2605469A1 (de)	1977-09-15
NL7701255A (nl)	1977-08-16
IE44440B1 (en)	1981-12-02
IT1075115B (it)	1985-04-22
IL51412A0 (en)	1977-04-29
BE851404A (fr)	1977-08-16
FR2340955B1 (fr)	1979-03-02
GB1567547A (en)	1980-05-14
DE2605469C3 (de)	1980-04-10
DK59377A (da)	1977-08-13
OA05567A (fr)	1981-04-30

Legal Events

Date	Code	Title	Description
1990-10-31	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE3001585C2 (de)	1985-05-15	Verfahren zur Herstellung von Interferon Typ I und II
DE2854381A1 (de)	1979-06-21	Verfahren zur gewinnung des antihaemophilen faktors viii aus blut, blutplasma oder blutplasma-fraktionen
DE3014189A1 (de)	1981-10-15	Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
US4421746A (en)	1983-12-20	Process for producing interferon inducers
DE3236126A1 (de)	1983-04-14	Verfahren zur herstellung von zur intravenoesen verabreichung geeignetem (gamma)-globulin
CH638562A5 (en)	1983-09-30	Process for obtaining a cleavage product of rabies virus
US5077202A (en)	1991-12-31	Process for producing a glycolipid having a high eicosapentaenoic acid content
DE2001902A1 (de)	1971-08-12	Verfahren zur Anreicherung von Proteinen
DD300833A7 (de)	1992-08-13	Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
DE2950004C2 (de)	1991-04-18	Verfahren zur Herstellung von Frühsommer-Meningoenzephalitis-Virus(FSME-Virus)-Vakzinen
US3436413A (en)	1969-04-01	Process for the isolation of phosphatidyl serine
DE2508396A1 (de)	1975-10-23	Verfahren zur gewinnung von virusproteinen, die dabei erhaltenen proteine und diese proteine als wirkstoffe enthaltende arzneimittel
IL39924A (en)	1976-09-30	Hormone isolated from the parathyroid gland,its preparation and compositions containing it
EP0315085B1 (fr)	1992-12-30	Protéine riche en histidine et recombinante de plasmodium falciparum, sa synthèse et son utilisation
DE2428955A1 (de)	1975-03-13	Verfahren zur extraktion von bestandteilen mit in vivo antikoagulierender wirkung aus schlangengiften und daraus erhaltene produkte
DE2447050A1 (de)	1975-04-10	Verfahren zur gewinnung von proteasenhemmstoff
US4495096A (en)	1985-01-22	Process for producing and obtaining anaphylatoxin-and cocytotaxin-containing leucotaxine preparations and of anaphylatoxin and cocytotaxin proteins in molecularly homogeneous, biologically active form
DE2333884A1 (de)	1974-01-31	Verfahren zur herstellung von gereinigtem albumin und das dabei erhaltene gereinigte albumin
DE2023987C3 (de)	1979-05-03	Verfahren zur Spaltung von Viren
DE3323093A1 (de)	1984-01-05	Pharmazeutisches praeparat
EP0049424B1 (fr)	1986-07-23	Composition bio-active contenant des agents végétaux
JPS6013004B2 (ja)	1985-04-04	インタ−フエロン誘起剤の製法
DD228737A1 (de)	1985-10-23	Verfahren zur herstellung von influenza-inaktivimpfstoffen mit geringer stammabhaengigkeit
DE1767099B1 (de)	1972-02-03	Verfahren zur Gewinnung eines Glykoproteins mit einer Hemmwirkung gegenueber Magensaeureabsonderung und einer Antiaktivitaet gegenueber Ulcus-Bildung
DE3907162C2 (fr)	1992-05-21